Abstract
THE DEVELOPMENT of effective fibrinolytic (thrombolytic) agents has offered new hope for the treatment of vascular thrombosis and emboli. Many investigations have reported significant improvement over the results obtained by other means of therapy in large numbers of patients with venous thrombosis, pulmonary embolus, and peripheral arterial thrombosis or embolus. Other conditions which have been treated satisfactorily include central retinal vein and artery thrombosis. Cerebral and coronary thrombosis remain, in the opinion of almost all investigators, a subject which requires prolonged investigation before an opinion concerning usefulness of these agents can be offered. 1 As with many such developments, there has been difference of opinion among investigators concerning specific types of materials to be used to produce the activity desired. This has been compounded in the case of fibrinolysin (Thrombolysin) because of the inability to develop truly objective methods of testing for activity and response. As a result strong opinions
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
